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Background: To assess the efficacy of concurrent chemoradiotherapy (CCRT) with daily low-dose cisplatin (CDDP)
plus weekly docetaxel (DTX) for patients with T2N0 glottic cancer.
Methods: Between January 2004 and December 2013, 62 treatment-naive patients with histologically proven T2N0
glottic cancer were treated with concurrent chemoradiotherapy. Radiation therapy (RT; 2 Gy daily fractions up to a
total dose of 66 Gy) was administered in combination with daily low-dose CDDP (6 mg/m2, five times a week), plus
weekly DTX (10 mg/m2) for up to 4 weeks from the commencement of RT.
Results: Median duration of follow-up was 70 months. The actuarial 3-year and 5-year overall survival rates were 95%
and 93%. The 3-year and 5-year cause-specific survival rates were both 100%. The actuarial 3-year and 5-year local
control rates were 94% and 94%, respectively. Hematologic toxicity (neutoropenia of severity≥ Grade 3) was observed
in 8% of the patients, and non-hematologic toxicity (radiation mucositis of severity ≥ Grade 3) developed in
one patient (2%). Radiation dermatitis of severity ≥ Grade 3 and laryngeal necrosis developed in one patient.
Conclusion: CCRT with weekly DTX and low-dose CDDP appears to be a practical and safe modality and is
expected to improve local control.
Trial registration: UMIN000025046. Registered 1 October 2015, retrospectively registered.
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A key focus in the management of laryngeal cancer is to
improve survival with functional preservation. In particu-
lar, radiation therapy (RT) at an early stage is an important
strategy for voice preservation in these patients. The local
control rate with RT alone for T1 glottic cancer is of the
order of 80 to 95%, whereas that for T2 disease is 70 to
80% [1–6]. These results suggest that conventional RT
alone may not achieve satisfactory local control in patients
with T2 disease.* Correspondence: junsaito@gunma-u.ac.jp
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the local control of T2 glottic cancer, including hyper-
fractionated radiotherapy (HFRT) and accelerated frac-
tionated radiotherapy (AFRT). Some earlier reports on
altered fractionated radiotherapy indicated improved
local control in patients with T2 glottic cancer. However,
two recent prospective randomized trials of conventional
fractionated radiotherapy (CFRT) versus HFRT/AFRT
did not show a statistically significant difference in out-
comes between the two groups. The 5-year local control
rate was reported to be in the range of 70 to 78% [7, 8].
Concurrent chemoradiotherapy (CCRT) is another ap-
proach to improve local control. Docetaxel (DTX) was
shown to enhance radiation sensitivity in pre-clinical
studies [9–11]. The potential mechanisms of thisle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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synchronization, apoptosis, and reoxygenation. Several
pre-clinical studies have suggested that cisplatin (CDDP)
also modulates radiation cell damage effectively [12, 13].
At our institute, the CCRT regimen used for patients
with T2 glottic cancer includes low-dose daily adminis-
tration of CDDP plus weekly administration of DTX.
Initial results were first reported in 2006 [14]. Five-year
disease-free survival in patients who received RT alone
(n = 25) and those who received CCRT (n = 25) were
70.9 and 91.8%, respectively. CCRT became a standard
treatment option for patients with T2N0 laryngeal can-
cer with adequate renal and liver function and a reason-
ably good performance status.
In this series, an evaluation of the long-term follow-up
outcomes of CCRT in 62 consecutive patients with
T2N0 glottic cancer are presented.
Methods
Patients
Between January 2004 and December 2013, 62 (59 men
and three women) patients with histopathologically con-
firmed T2N0 glottic cancer were treated with CCRT at
our institute. The regimen consisted of RT plus daily ad-
ministration of low-dose CDDP and weekly DTX. Me-
dian age of patients was 71 years (range, 51–88 years).
The main eligibility criteria for CCRT were as follows:
(i) patients with previously untreated, histologically
proven, T2N0M0 glottic cancer; (ii) no previous history
of regional RT; (iii) Eastern Cooperative Oncology
Group performance status ≤2; (iv) sufficient organ func-
tion for chemoradiotherapy.
Sixty one patients had squamous cell carcinoma, and
one patient had undifferentiated carcinoma. The distri-
bution of the primary sites was as follows: supraglottic
extension, 58 patients; subglottic extension, two patients;
supraglottic and subglottic extension, two patients. Writ-
ten informed consent to the treatment was obtained
from all patients prior to commencement of the
treatment.
Treatment
The RT dosage schedule was 2 Gy per fraction, once a day
up to a total dose of 66 Gy in 33 fractions, over a period
of 7 weeks, in principle. The gross tumor volume (GTV)
was assessed by laryngeal fiberscope or other diagnostic
imaging such as computed tomography. The clinical tar-
get volume (CTV) included the GTV and the entire vocal
cords. The planning target volume (PTV) included the
CTV plus a 0.5-cm margin in the anteroposterior axis,
and a 0.5–1-cm margin in the craniocaudal axis.
All patients were treated with 4 or 6 MV photons by
parallel-opposed bilateral fields with portal dimension of
generally 6 × 6 cm centered over the thyroid cartilage.Elective irradiation to cervical lymph nodes was not per-
formed. In this series, prescribed doses of RT were cal-
culated at the central axis without heterogeneity
correction.
The chemotherapeutic regimen consisted of daily low-
dose CDDP plus weekly administration of DTX. CDDP
(6 mg/m2, five times a week) was administered for up to
4 weeks (total dose of CDDP: 120 mg/m2) and DTX
(10 mg/m2, once a week) was administered for up to
four cycles from the commencement of RT in patients
with adequate renal function, as determined by creatin-
ine clearance (CCr). In the event of a fall in CCr below
60 mL/min, DTX alone (10 mg/m2, once a week) was
administered for up to 4 weeks. RT was performed as
soon as possible after the administration of chemother-
apy. Granulocyte-colony stimulating factors were not
used except for patients with febrile neutropenia or
those with Grade 4 leukopenia or neutropenia. Patients
who experienced hematological toxicity > Grade 3 were
made to skip chemotherapy. Toxicity was assessed using
the National Cancer Institute Common Toxicity Criteria
for Adverse Events, version 4.0. Local response was
assessed 1 month after the completion of RT on laryn-
geal fiberscope or by computed tomography scan of the
head and neck region.
Statistics
All statistical analyses were performed with IBM SPSS
Statistics for Windows, version 21.0 (SPSS Inc., Armonk,
NY, USA). The survival time was measured from the
first day of treatment to the date of death or the date of
most recent follow-up. The Kaplan–Meier method was
employed to determine the actuarial survival rate and
local control rate. Prognostic relevance of variables was
assessed using log-rank test.
Results
The median total irradiated dose was 66 Gy (range, 62–
70 Gy), and the median overall duration of RT was 48 days
(range, 43–52 days). Forty four patients completed the
prescribed chemotherapy regimen (completion rate, 71%).
In the remaining 18 patients, the reasons for interruption
of chemotherapy included renal dysfunction (n = 15),
grade 3 neutropenia (n = 1), liver dysfunction (n = 1), and
drug eruption with oral mucositis (n = 1).
Median duration of follow up was 70 months (range,
8–139 months).
The Kaplan–Meier overall survival (OS), cause-specific
survival (CSS), and progression-free survival (PFS)
curves from the initial treatment are shown in Figs. 1
and 2. The actuarial 3-year and 5-year OS rates were 95
and 93%, respectively. The 3-year and 5-year CSS rates
were both 100%; the 3-year and 5-year PFS rates were
89 and 87%, respectively. Death from causes unrelated
Fig. 1 Overall survival from the start of treatment Fig. 3 Local control rate during the follow-up period
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infarction (n = 1), cerebral bleeding (n = 1), esophageal
cancer (n = 1), lung cancer (n = 1), and pneumonia (n = 1)].
The initial local tumor response was evaluated in all
patients. Fifty nine patients achieved a complete re-
sponse while three patients showed a partial response
and experienced disease progression 4 to 7 months after
the start of treatment. Analysis of the failure patterns re-
vealed progression only within the irradiation field in
these three patients, and in additional two patients on
extended follow up (78 months from the treatment).
Progression outside the irradiation field was never ob-
served as of the most-recent follow-up.
The local control rate during the follow-up period is
shown in Fig. 3. The actuarial 3-year and 5-year local
control rates were both 94%. In these five patients with
local recurrence, three patients completed the prescribed
regimen of CCRT, while the other two patients could not
complete chemotherapy because of renal dysfunction.Fig. 2 Cause-specific (solid dotted) and progression-free (solid line)
survival from the start of treatmentSalvage surgery was performed in all five patients who ex-
perienced local recurrence. Four patients underwent total
laryngectomy, one underwent larynx conserving surgery;
all patients were salvaged from the disease. Another pa-
tient lost his larynx because of laryngeal necrosis after the
treatment, so the actuarial 3-year and 5-year preservation
rates of the larynx were both 94%, respectively. In a pa-
tient with late local recurrence (78 months after treat-
ment), final pathological diagnosis at salvage surgery was
adenosquamous carcinoma.
Hematologic and non-hematologic toxicities are sum-
marized in Table 1. Among hematologic toxicities, neu-
toropenia of severity ≥Grade 3 was observed in 8% of
the patients. Of the non-hematologic toxicities, radiation
mucositis of severity ≥Grade 3 occurred in one patient
(2%), while Grade 1/2 mucositis was noted in fifty pa-
tients (97%). Dermatitis of severity ≥Grade 3 was ob-
served in one patient, and this patient also experienced
laryngeal necrosis.
Discussion
Functional preservation is a key objective in treatment
of head and neck malignancies. Comparable rates ofTable 1 Treatment related adverse events
Toxicity Grade
0 1 2 3 4 ≥Grade 3 (%)
Leukopenia 26 16 17 3 0 5
Neutropenia 32 14 11 5 0 8
Anemia 28 31 3 0 0 0
Thrombocytopenia 33 27 2 0 0 0
Mucositis 1 15 45 1 0 2
Dermatitis 1 58 2 1 0 2
Hoarseness 45 12 4 1 0 2
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control, and survival were reported in patients with T1-
T2 glottic cancer treated with transoral laser excision,
open partial laryngectomy, and RT [15]. American Soci-
ety of Clinical Oncology clinical practice guidelines rec-
ommend that patients with T1-T2 laryngeal cancer
should be treated with the intent to preserve the larynx
and that these patients can be treated with RT or larynx-
preservation surgery with similar survival outcomes [16].
Some retrospective studies show approximately 70 to 80%
5-year local control with use of CFRT alone for T2 glottic
lesions [1–6]. In this series, 62 patients with T2N0 glottic
cancer who were treated by CCRT (RT and daily low-dose
administration of CDDP plus weekly administration of
DTX) had 5-year CSS, PFS, and local control rates of 100,
89, and 94%, respectively. These treatment results seemed
to be comparable or superior to those of patients with T1
glottic cancer treated by RT alone [1–6].
High dose CDDP plus RT is recommended for the
treatment of locally advanced head and neck cancers
[17]. However, for the treatment of T2N0 glottic cancer,
RT alone may achieve 70 to 80% local control and the
purpose of concomitant use of chemotherapy is 10 to
15% gain by radiosensitization. It is conceivable that
CCRT may be an overtreatment in some cases with T2
disease, but RT and daily low-dose administration of
CDDP plus weekly administration of DTX regimen was
well tolerated in some elderly patients, and 71% of all
patients were able to complete the prescribed chemo-
therapy regimen. A completion rate of chemotherapy
(71%) was not so high, but the priority of the treatment
is the accomplishment of RT and the issue of safety, and
the stopping rule of chemotherapy (concerning the use
of cisplatin) was strict (The event of a fall in creatinine
clearance below 60 mL/min, corresponsive to grade 1
adverse event). As for the other adverse events of CCRT,
both radiation mucositis of severity ≥Grade 3 and radi-
ation dermatitis of severity ≥Grade 3 occurred in 2% of
all patients. One patient experienced laryngeal necrosis
eight months after the initial treatment, for which total
laryngectomy was performed. Grade 3 dermatitis was
observed only in this patient, and chemotherapy was
stopped midway through the prescribed regimen (total
dose of RT was 64 Gy). The reason for severe adverse
event in this patient is not clear, but this patient may
have developed hypersensitivity to RT or chemotherapy.
Altered fractionation of RT schedule is one of the ap-
proaches used to improve tumor control. Garden per-
formed a retrospective analysis of use of RT for T2
glottic cancer, and concluded that patients treated with
HFRT (median dose: 77 Gy) showed improved local con-
trol from that of patients treated with CFRT [18]. More-
over, patients treated with AFRT (daily fraction sizes of
2.06–2.26 Gy) also showed improved local control fromthat achieved with CFRT (5-year local control rate:
CFRT 59%, HFRT 79%, AFRT 82%). Motegi reported a
5-year local control rate of 77% in patients with early
glottis cancer (T2) treated with AFRT (2.4 Gy once-daily
fractionation) [19]. None of the patients experienced se-
vere acute toxicity; while 2 out of 44 patients developed
severe late toxicity (arytenoid edema). Thus, the trend
and spotlight of treatment strategy of early stage glottic
cancer has been a prospective randomized trial of CFRT
versus HFRT/AFRT. Two recently reported prospective
randomized trials in patients with glottic cancer showed
no significant difference between CFRT and HFRT/
AFRT [7, 8]. In the RTOG 9512 trial, the 5-year local
control rate with HFRT (79.2 Gy in 66 fractions of
1.2 Gy administered twice a day) was modestly but not
significantly higher than that with CFRT (78% vs. 70%;
P = 0.14) [7]. KROG-0201 was a prospective randomized
trial of AFRT (63 Gy/28 fractions for T1 and 67.5 Gy/30
fractions for T2) versus CFRT in patients with T1–2
glottic cancer. Of the enrolled patients, 89% had T1 dis-
ease. The 5-year local progression-free survival in the
CFRT and AFRT arms was 77.8 and 88.5%, respectively
(P = 0.213). A significant superiority of AFRT with re-
spect to local control is yet to be demonstrated in ran-
domized trials.
In T2 glottic cancer, chemoradiotherapy may achieve
better tumor control than that achieved with RT alone.
However, there are only a few reports from prospective
randomized trials of chemoradiotherapy in these pa-
tients. Much of the available evidence emanates from
retrospective studies. Itoh reported a 5-year local control
rate of 91% with CCRT in a study of 11 patients with T2
glottic cancer [CFRT (total dose: 60 Gy) plus protracted
continuous infusion of low-dose CDDP and 5-
fluorouracil] [20].
Hirasawa et al. performed a retrospective multi-
institutional analysis of 270 patients with T1–2 glottic
cancer. The chemoradiotherapy group showed a ten-
dency for superior local control in patients with T2 dis-
ease when compared with the RT group [21]. In this
multi-institutional analysis, the regimen of chemother-
apy varied in different treatment facilities. The 5-year
local control rate was 66.4% for RT alone and 80.7% for
chemoradiotherapy (P = 0.149).
Nakayama et al. reported the results of Phase I/II trial
of concurrent use of orally administered S-1 and RT for
T2 glottic cancer [22]. The use of S-1 at a daily dose of
80 mg/m2 with a 1-week break during the course of
CFRT (60 Gy in 30 fractions) was reported to be safe
and associated with a 3-year local control rate of 94.7%.
The number of treated patients was relatively small
(n = 19) and the findings need to be confirmed in a larger
study. However, this is a rare report of prospective trial of
CCRT for treatment of T2 glottic cancer.
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tive patients who were treated by CCRT (RT and daily
low-dose CDDP plus once-weekly DTX) were retro-
spectively investigated. The 5-year local control rate was
94%. A limitation of this regimen (weekly DTX and low-
dose CDDP) is the need for hospitalization for drug and
fluid infusion. Furusaka et al. reported the results of
CCRT with once-weekly or twice-weekly DTX (10 mg/
m2) with CFRT (total dose: 66 Gy). The 5-year laryngeal
preservation rates were 83.8% in the once-weekly com-
bination group and 97.6% in the twice-weekly combin-
ation group. The 5-year laryngeal preservation rate was
60.4% in the 57 patients who were treated with CFRT
alone [23]. Once or twice weekly DTX may be adminis-
tered in an outpatient setting, which is an advantage of
CFRT with twice-weekly DTX.
Conclusion
The feasibility and efficacy of CCRT with weekly DTX
and low-dose CDDP for patients with T2N0 glottic can-
cer was confirmed in this series. The actuarial 3-year
and 5-year OS rates were 95% and 93%, respectively.
The actuarial 3-year and 5-year local control rates were
both 94%, respectively. CCRT for T2 glottic cancer is
not always fundamental in every facility; however, CCRT
with weekly DTX and daily low-dose CDDP appears to
be a safe and promising therapeutic modality and im-
provement in local control might be expected.
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